INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion

16,07 USD
+4,15 %+0,64
6. Nov, 23:23:32 Uhr, UTP Consolidated
Kommentare 427
Summer.76
Summer.76, 14.11.2022 5:58 Uhr
0
https://www.fiercebiotech.com/biotech/intellia-ready-talk-functional-cure-hae-interim-data-hand-second-gene-editing-candidate
Summer.76
Summer.76, 03.11.2022 12:39 Uhr
0
https://www.globenewswire.com/news-release/2022/11/03/2547478/0/en/Intellia-Therapeutics-Announces-Third-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html
Summer.76
Summer.76, 31.10.2022 14:53 Uhr
0
https://www.globenewswire.com/news-release/2022/10/31/2544470/0/en/Intellia-Therapeutics-to-Present-Updated-Interim-Clinical-Data-from-Ongoing-Phase-1-2-Study-of-NTLA-2002-for-the-Treatment-of-Hereditary-Angioedema-at-the-2022-ACAAI-Annual-Scienti.html
Solix
Solix, 14.10.2022 20:17 Uhr
0
🎈
Summer.76
Summer.76, 16.09.2022 19:10 Uhr
0
Intellia Investors Are Dumping Stock on News of Crispr Gene-Editing Success https://www.shareandstocks.com/intellia-investors-are-dumping-stock-on-news-of-crispr-gene-editing-success/
Summer.76
Summer.76, 01.09.2022 22:30 Uhr
0
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema https://www.globenewswire.com/news-release/2022/09/01/2508902/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2002-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Hereditary-Angioedema.html • NTLA-2002, an in vivo genome editing candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) after a single dose, is currently being evaluated in a Phase 1/2 study ...
Summer.76
Summer.76, 23.08.2022 16:51 Uhr
0
https://www.globenewswire.com/news-release/2022/08/23/2503154/0/en/Intellia-Therapeutics-to-Present-Interim-Clinical-Data-from-Ongoing-Phase-1-2-Study-of-NTLA-2002-for-the-Treatment-of-Hereditary-Angioedema-at-the-2022-Bradykinin-Symposium.html
Summer.76
Summer.76, 04.08.2022 18:04 Uhr
0
Intellia Therapeutics down 12% following bottom line Q2 earnings miss https://seekingalpha.com/news/3867319-intellia-therapeutics-down-12-following-bottom-line-q2-earnings-miss?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain • Intellia Therapeutics (NASDAQ:NTLA) is down 12% in Thursday morning trading after it missed analyst estimates on Q2 2022 EPS. • The company's net loss in the quarter widened ~46% to ~$100.7M compared to the prior-year period (-$1.33 per share, basic and diluted vs. $1.01). • Revenue of ~$14M, a 114% year-over-year increase, was a beat. • Intellia (NTLA) was weighed down in the quarter by a significant increase in operating expenses, which went up ~49% to $112.3M. R&D expenses alone rose 53% to ~$90.2M. • The company ended the quarter with $906.9M in cash and cash equivalents compared to compared to $1.1B on Dec. 31, 2022.
L
Longie41, 04.08.2022 17:40 Uhr
1
Das ist der Grund für den heftigen Kursrückgang heute: https://www.fiercebiotech.com/biotech/intellia-looks-tack-lower-dose-polyneuropathy-trial-arm-after-elevated-liver-levels
Summer.76
Summer.76, 04.08.2022 16:08 Uhr
0
Gestern ging es halt ordentlich aufwärts ohne news (und wohl befeuert durch Alnylam). Mal schauen, wo sie sich heute 'einpendelt'.
S
Steffen2012, 04.08.2022 15:53 Uhr
0
Ich habs echt nur überflogen, also womöglich etwas überlesen. Aber warum dropped es denn so? Viel cash und nichts schlimmes was die Studien angeht. Daten in H2 22 erwartet. Hab ich was übersehen?
Summer.76
Summer.76, 04.08.2022 15:24 Uhr
0
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress https://www.globenewswire.com/news-release/2022/08/04/2492214/0/en/Intellia-Therapeutics-Announces-Second-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html
G
Gast-729245900, 24.06.2022 14:15 Uhr
1
https://www.globenewswire.com/news-release/2022/06/24/2468698/0/en/Intellia-and-Regeneron-Present-Updated-Interim-Data-from-Phase-1-Study-of-CRISPR-based-NTLA-2001-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis-Demonstrating-that-Deep-Serum-T.html
Summer.76
Summer.76, 08.06.2022 21:15 Uhr
0
https://www.globenewswire.com/news-release/2022/06/08/2458609/0/en/Intellia-Therapeutics-to-Present-Updated-Interim-Clinical-Data-from-Ongoing-Phase-1-Study-of-NTLA-2001-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis-at-the-International-Live.html
Summer.76
Summer.76, 05.05.2022 15:09 Uhr
0
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress https://www.globenewswire.com/news-release/2022/05/05/2436692/0/en/Intellia-Therapeutics-Announces-First-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html
Summer.76
Summer.76, 02.05.2022 16:24 Uhr
0
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference https://www.globenewswire.com/news-release/2022/05/02/2433370/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-CRISPR-Engineered-Allogeneic-Platform-at-the-2022-Keystone-Symposia-s-Precision-Genome-Engineering.html • Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell therapy • Findings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the treatment of CD30-expressing hematologic cancers
Meistdiskutiert
Thema
1 SOLAREDGE TECH Hauptdiskussion -36,41 %
2 Phunware ab 27.02.24 RS +11,15 %
3 DAX Hauptdiskussion -0,92 %
4 PLUG POWER Hauptdiskussion -21,83 %
5 Phunware Hauptdiskussion +11,15 %
6 Plug Power ohne Spam -21,83 %
7 AMC ENTERTAINMENT Hauptdiskussion -2,05 %
8 ALBEMARLE Hauptdiskussion -5,62 %
9 VW Hauptdiskussion -4,73 %
10 Nio für normale Kommunikation -4,93 %
Alle Diskussionen
Aktien
Thema
1 SOLAREDGE TECH Hauptdiskussion -36,41 %
2 Phunware ab 27.02.24 RS +10,35 %
3 PLUG POWER Hauptdiskussion -21,83 %
4 Phunware Hauptdiskussion +10,35 %
5 Plug Power ohne Spam -21,83 %
6 AMC ENTERTAINMENT Hauptdiskussion -2,05 %
7 ALBEMARLE Hauptdiskussion -5,62 %
8 VW Hauptdiskussion -4,73 %
9 Nio für normale Kommunikation -4,93 %
10 NEL ASA Hauptdiskussion -8,20 %
Alle Diskussionen